Guix Arnau, Marta (Date of defense: 2017-12-19)
Targeted therapies against the Epidermal Growth Factor Receptor (EGFR) are useful to treat many human cancers such as non-small cell lung cancer, colorectal cancer and head and neck cancer. However, the ...
Cañadas Castillo, Israel (Date of defense: 2013-06-25)
Small cell lung carcinoma (SCLC) is a highly lethal disease due to its chemorefractory nature after first line treatment. The mechanisms to overcome this resistance have remained elusive to tackle up ...
Guardia Valenzuela, Cristina (Date of defense: 2019-12-19)
El cáncer de mama HER2-positivo es un subtipo muy agresivo. El desarrollo de terapias anti-diana HER2, particularmente el anticuerpo monoclonal (Mab) trastuzumab, supuso una mejora significativa en el ...
Soria Jiménez, Luis (Date of defense: 2023-02-17)
Although the dual anti-HER2 blockade with trastuzumab and pertuzumab monoclonal antibodies has improved the outcome of patients with HER2+ breast cancer, a significant number of patients relapse. ...
Suárez Olmos, Jesús (Date of defense: 2023-11-30)
Several studies support the contribution of antibody-dependent NK cell cytotoxicity (ADCC) to the clinical efficacy of anti-HER2 therapeutic antibodies in HER2-positive breast cancer. Novel anti-HER2 ...
García Parra, Jetzabel (Date of defense: 2012-06-21)
Breast cancer is the main cause of cancer death in women. Improved treatments, prevention programs and earlier detection are reducing the rate of death; however, there is still a high percentage of ...
Dalmases Massegú, Alba (Date of defense: 2012-06-22)
EGFR is a transmembrane tyrosine kinase receptor from the HER family which, upon ligand stimulation, activates different signaling pathways involved in tumorogenesis. EGFR can be targeted by monoclonal ...